Across industries, these three founders found a new way of doing things. Images courtesy

This week's innovators to know truly represent the spirit of innovation. All three looked at a traditional way of doing something, and reimagined it — from design to smart technology.

Andre Norman, founder of Jellifin

Andre Norman founded Jellifin, an options trading platform, flipping the script on the traditional investment process. Courtesy Jellfin

When it comes to investing in stock options, you might go the traditional route and seek out a brokerage that focuses on options trading. There's a major catch, though: most brokerages tack on a fee of anywhere between $7 and $20 per trade, says Andre Norman, founder of Jellifin, an online options trading platform, is disrupting that norm.

The company works with individuals and brokers to provide an options trading platform at a flat monthly fee. This allows investors to trade as frequently or infrequently as they please, and to not factor in the cost of a trade fee when considering what's best for their portfolio.

"A lot of people don't invest because of the high costs associated with trading," Norman said. "We allow them to get into investing without having to pay huge amounts of money."

Read more about Jellifin and its founder here.

Lisa Pope Westerman, founder and CEO of LUCID

Lisa Pope Westerman has created LUCID, a network of architects that's flipping the script on how architecture projects go. Courtesy of LUCID

When it comes to the traditional method of design integration, Lisa Pope Westerman saw a disconnect. She created LUCID, a collective of architects and boutique architecture firms, to help connect the dots within the industry. When clients retain LUCID as their designer or architect, they're given access to the firms and individual architects who are best suited for the job.

"People have referred to us as 'the WeWork of architecture,' or 'the Uber of design,'" Pope Westerman says. "We think that in 10 years, this is how the world will just be working."

Read more about LUCID and its founder here.

Marci Corry, owner of SAFE 2 SAVE

Marci Corry had the idea for SAFE 2 SAVE in 2016 when she met with a college student she was mentoring to discuss how to help the student's peers detach from their phones. They agreed that incentives, particularly food, were the key, and not just for college kids. Now, the Houston-based app has blown up to include a fan base of more than 148,000 users, 20 employees, and a partnership with Memorial Hermann.

"They said, 'We want this to stop happening. We don't want these people being pushed through our door on a stretcher and this is epidemic in Houston,'" Corry says.

Read more about SAFE 2 SAVE and its founder here.

Lisa Pope Westerman has created LUCID, a network of architects that's flipping the script on how architecture projects go. Courtesy of LUCID

Meet the Houston entrepreneur behind the 'Uber of design'

Featured Innovator

What if retaining one architecture company gave you access to dozens more? That's the idea behind LUCID, an architecture and design collective that Lisa Pope Westerman, formerly of San Francisco-based Gensler and New York City-based rockwell group, launched in Houston this year.

LUCID is a collective of architects and boutique architecture firms that specialize in at least one of the following property types: hospitality, retail, mixed-use developments, high-rise residential, and wellness developments. When clients retain LUCID as their designer or architect, they're given access to the firms and individual architects who are best suited for the job. Currently, LUCID is composed of roughly 40 total architects coming from several architecture and design firms, including Chicago-based PinPoint Collective, Houston-based gin design group, and New York-based Glen & Co. architecture.

"People have referred to us as 'the WeWork of architecture,' or 'the Uber of design,'" Pope Westerman says. "We think that in 10 years, this is how the world will just be working."

Pope Westerman spoke with InnovationMap about launching LUCID, Houston's unique design community and how the architecture industry continues to innovate.

InnovationMap: When did you start planning LUCID?

Lisa Pope Westerman: I really started thinking about it in beginning of 2018, and working on it middle of 2018, and making sure the initial groups we started with are a good fit. It's been nothing but wonderful. Everyone's smarter than me, and brings such a unique perspective to the group for various reasons. Not everyone is an architect or an interior designer ­– the intent is to be really nimble and flexible. We're bringing a lot of unique specialists. We have branding, graphic design, and a strategy group that is just amazing.

We're looking to, as a group, not just be innovative, but have innovation in all the different types of things [we offer], including our process. We believe that the world of design is going to be much more than visual, and that we really need to be thinking about all the senses, like touch and smell and [hearing]. Just typically, everything's visual, and [the other senses] have been secondary.

IM: How did LUCID find the architects and architecture firms that compose the collective?

LPW: The original of roughly 40 people are people I've worked with over the past 20 years. That's how we got things started. I've basically been involved in every size company imaginable: from a one-man show, to the largest design firm in the world, Gensler. The intent of the model is to create something where there's a parent brand that feels like a very large company, and we're essentially an umbrella, and within us are all the other wonderful boutique specialty brands.

IM: What kinds of architecture firms does LUCID work with?

LPW: Most of the firms affiliated with us are around a dozen people. We find that's the right size of people that are highly specialized, super talented, and able to maintain the [high] quality level.

IM: Tell me a bit about LUCID's business model.

LPW: So, we facilitate everything, and that's how [LUCID] is compensated. So, we essentially facilitate in bringing the companies to the client, which is the business development aspect of things. We collaborate on the client management side, so we're still very involved with the clients and the projects. We carry everybody. We help manage all of it, and all of the companies' [projects]. It's a true collaboration.

People truly believe that by being associated with LUCID, they're going to be able to elevate what they've been doing even more. It's important that the companies that want to be affiliated with LUCID are really interested in that.

IM: Can the architecture firms that are a part of LUCID still do work outside of the LUCID collective?

LPW: All the firms connected to LUCID still do their own business. They haven't folded into LUCID and then given up their brand. The intent is that we're celebrating the brands. We like the diversity.

IM: LUCID is currently working on its first project. What information can you share?

LPW: It's in the hospitality industry, and it is a restaurant, bar, event space, and it's for a private club outside of Houston. We started at the beginning of [2019], and we'll be done at the end of the year.

IM: Did LUCID launch with a fund raise? Are you planning a fund raise?

LPW: The front end is really just a shared passion among the companies and individuals that are connected. Longer term, we are interested in even partnering with investors in creating new and different kinds of projects. There are some other firms out there, but not many, that are starting to do that sort of thing … where [the design firm] collaborates with investors and projects, rather than just being hired on as the designer for a project.

IM: How is the Houston design scene different from design scenes around the world?

LPW: Well, I think it's an exciting time for Houston. Especially in our world of lifestyle design, it's the overarching [theme]. We do everything for lifestyle. In Houston, we're really starting to be at the height of this renaissance of bringing just a higher level of appreciation for design. From a lifestyle standpoint, things have been percolating for a while now.

IM: What's a foundational project you've worked on that taught you an essential lesson about design?

LPW: In terms of my Houston project base, certainly the ExxonMobil project was really impactful, because of the scale of the project and all the different participants in it. We collaborated with several other design firms, both in Houston and out of Houston, and not only design firms, but also globally acclaimed artisans. Just at a worldwide level, the caliber of the clients was amazing. It was an incredible experience because of the scale and the success of it. … It was building a city.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.